Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC

NCT07491497 is registered in ClinicalTrials.gov with TRIANA Biomedicines, Inc. as lead sponsor.

NCT NCT07491497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07491497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Dose Escalation and Expansion Study of TRI-611, an Oral ALK Molecular Glue Degrader in Participants With Advanced ALK-Positive NSCLC
Lead sponsor
TRIANA Biomedicines, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
March 11, 2026
Completion date
January 30, 2034
Enrollment
160 (estimated)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

alk-positive lung cancer, alk-positive non-small cell lung cancer, alk-positive nsclc